Back to Browse Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 2

Update on terbinafine with a focus on dermatophytoses

Authors Jason G Newland, Susan M Abdel-Rahman

Published Date April 2009 Volume 2009:2 Pages 49—63

DOI http://dx.doi.org/10.2147/CCID.S3690

Published 21 April 2009

Jason G Newland1,3, Susan M Abdel-Rahman2,3

Divisions of Infectious Diseases1 and Clinical Pharmacology and Medical Toxicology2, Children’s Mercy Hospitals and Clinics, Kansas City, MO, USA; 3Department of Pediatrics, University of Missouri-Kansas City, School of Medicine, Kansas City, MO, USA

Abstract: Since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungal infections, aided by unique pharmacologic and microbiologic profiles. This article reviews mode of action, antimycotic spectrum and disposition profile of terbinafine. It examines the data, accumulated over 15 years, on the comparative efficacy of terbinafine (vs griseofulvin, itraconazole, fluconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.

Keywords: tinea, Trichophyton, Microsporum, allylamine, antifungal

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

The Creating Hope Act: what is old is new again

Tolbert JA, Goldman JL, Kauffman RE, Abdel-Rahman SM

Pediatric Health, Medicine and Therapeutics 2014, 5:49-57

Published Date: 3 June 2014

Readers of this article also read:

Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses

Hideki Hasegawa, Takeshi Ichinohe, Akira Ainai, Shin-ichi Tamura, Takeshi Kurata

Therapeutics and Clinical Risk Management 2009, 5:125-132

Published Date: 9 March 2009

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Retinoid plus antimicrobial combination treatments for acne

Feneran A, Kaufman WS, Dabade TS, Feldman SR

Clinical, Cosmetic and Investigational Dermatology 2011, 4:79-92

Published Date: 1 July 2011

Single intravitreal ranibizumab for myopic choroidal neovascularization

Nor-Masniwati S, Shatriah I, Zunaina E

Clinical Ophthalmology 2011, 5:1079-1082

Published Date: 4 August 2011

Characterization and evolution of dermal filaments from patients with Morgellons disease

Middelveen MJ, Mayne PJ, Kahn DG, Stricker RB

Clinical, Cosmetic and Investigational Dermatology 2013, 6:1-21

Published Date: 8 January 2013

Emerging treatment options for early mycosis fungoides

Fernandez-Guarino M

Clinical, Cosmetic and Investigational Dermatology 2013, 6:61-69

Published Date: 18 February 2013